Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
12/2003
12/30/2003US6670473 Inhibitors of nitric oxide synthase (nos)
12/30/2003US6670464 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
12/30/2003US6670401 Polysubstituted indan-1-ol compounds, and methods for their preparation and use
12/30/2003US6670389 Laulimalide derivatives
12/30/2003US6670380 Pyridone inhibitors of fatty acid binding protein and method
12/30/2003US6670359 Such as (S)-N-(5-(4-Methylpiperazin-1-yl)-3,4-dihydro-2H-1-benzopyran-3-yl)-4 -morpholinobenzamide for treatment of mood/anxiety/eating disorders
12/30/2003US6670346 Treatment and/or inhibition of the development of osteoporosis, breast cancer, hypercholesterolemia, hyperlipidemia or atherosclerosis in susceptible warm-blooded animals including humans, administering selective estrogen
12/30/2003US6670339 Use of sulfated oligosaccharides in lowering blood triglyceride levels
12/30/2003US6670136 Peptide for use in the treatment of inflammation defects
12/30/2003US6669952 Composition containing isoflavone material and plant sterol for reducing LDL-cholesterol
12/30/2003US6669941 Administering drugs comprising tumor necrosis factor adrenergic blocking agents conjugated to immunoglobulins for the prophylaxis of rheumatoid arthritis, multiple sclerosis or diabetes
12/30/2003US6668527 Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
12/30/2003CA2293621C 4-aminopyrrole(3,2-d) pyrimidines as neuropeptide y receptor antagonists
12/30/2003CA2291732C A salt (r)-3-n,n-dicyclobutylamino-8-fluoro-3,4-dihydro-2h-1-benzopyran-5-carboxaminde hydrogen (2r,3r)-tartrate
12/30/2003CA2093806C Method of treating or preventing type 1 diabetes by oral administration of insulin
12/29/2003WO2004002469A1 Isoflavone concentrate and method for production thereof
12/29/2003CA2448513A1 Isoflavone concentrates, as well as methods for their production
12/25/2003WO2003105888A1 Acidic insulin preparations with improved stability
12/25/2003WO2003105605A2 Use of pullulan as a slowly digested carbohydrate
12/25/2003US20030236417 A 4,5-Dihydro-2-(2,4-dihydroxyphenyl)-thiazole-4(S)-carboxylic acid or ester derivatives, use as iron metabolic chelators in therapeutic applications; demetallization
12/25/2003US20030236406 Amination forming a benzylammonium methyl phenoxy 5-tetrahydrobenzothiepine; apical sodium co- dependent bile acid transporter inhibitors, anticholesterol agents
12/25/2003US20030236405 7-hetero-bicyclo[2.2.1]-heptanes
12/25/2003US20030236402 A caspase-3 enzyme inhibitors, 3-(3-alkyl-amino-2-oxo-1,2-dihydro-1-pyrazinyl-alkanoylamino) -4-oxopentanoic acid; treating cardiac or cerebral ischemia or reperfusion injury, diabetes, AIDS
12/25/2003US20030236389 Proteins, polynucleotides encoding them and methods of using the same
12/25/2003US20030236309 Novel formate salt of O-desmethyl-venlafaxine
12/25/2003US20030236304 Fluorobenzamides and uses thereof
12/25/2003US20030236286 Central nervous system disorders; cardiovascular disorders; antiischemic agents; psychological disorders
12/25/2003US20030236281 Quinoline derivatives(2)
12/25/2003US20030236273 Aryl substituted pyrimidines and the use thereof
12/25/2003US20030236272 Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states
12/25/2003US20030236269 Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same
12/25/2003US20030236267 Benzimidazole derivatives
12/25/2003US20030236262 Dietetics; antidiabetic agents; sexual disorders
12/25/2003US20030236258 Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents
12/25/2003US20030236252 Brain disorders, cardiovascular disorders, strokes, Parkinson's disease
12/25/2003US20030236230 Comprises 4-substituted piperidine ring linked to a substituted or unsubstituted hydrocarbyl ring; for controlling weight gain in a human or higher mammal
12/25/2003US20030236227 Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
12/25/2003US20030236213 Compounds useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders
12/25/2003US20030236212 Compounds useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders
12/25/2003US20030236202 Natural products and derivatives thereof for protection against neurodegenerative diseases
12/25/2003US20030236193 Methods of treatment using specific binding agents of human angiopoietin-2
12/25/2003US20030235812 Diagnosing diabetic disorders via impaired insulin secretion, decreased adenine triphosphate biosynthesis and increased levels of reactive oxygen species
12/25/2003US20030235620 Animal extracts used as lipoxygenase inhibitors, antidiabetic, antiinflammatory, antiarthritic or antidiabetic agents; molluscs
12/25/2003US20030235609 Use of cholinesterase antagonists to treat insulin resistance
12/25/2003US20030235588 Thioredoxin (TRX); administering histone deacetylase inhibitors such as trichostatin A; for treating inflammation
12/25/2003US20030235585 Methods of treating disorders in which TFN alpha activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor alpha
12/25/2003US20030235558 Contacting a compound with a sample containing p62 and ubiquitin, determining level of p62/ubiquitin binding under normal conditions and in the presence of the compound and comparing the two levels
12/24/2003WO2003106669A1 Purified pkb ser 473 kinase and uses thereof
12/24/2003WO2003106660A2 Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier
12/24/2003WO2003106506A1 Low molecular weight oversulfated polysaccharide
12/24/2003WO2003106505A1 Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained
12/24/2003WO2003106504A1 Epimerized derivatives of k5 polysaccharide with a very high degree of sulfation
12/24/2003WO2003106482A1 Peptides derivatives comprising thiazepine group for the treatment of hyperlipidemic conditions
12/24/2003WO2003106474A2 Gangliosides with a modified acyl function
12/24/2003WO2003106462A1 Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
12/24/2003WO2003106459A1 Amide substituted xanthine derivatives with gluconeogenesis modulating activity
12/24/2003WO2003106456A2 New compounds
12/24/2003WO2003106455A1 Azole methylidene cyanide derivatives and their use as protein kinase modulators
12/24/2003WO2003106452A2 Antagonists of melanin concentrating hormone receptor
12/24/2003WO2003106441A1 Pharmaceutical salts of reboxetine
12/24/2003WO2003106435A1 Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof
12/24/2003WO2003106431A2 Novel hexahydro-pyridazine-3-carbocylic acid hydrazide or hydrazone derivatives, combinatorial libraries containing same, use thereof as medicines, pharmaceutical compositions containing same and methods for preparing same
12/24/2003WO2003106430A1 Benzimidazole inhibitors of poly(adp-ribosyl) polymerase
12/24/2003WO2003106428A1 Novel arylsulphonamide derivatives and use thereof as therapeutic agents
12/24/2003WO2003106423A1 Cyclic amine and medicinal composition containing the same
12/24/2003WO2003106418A1 Indole, indazole, and benzazole derivative
12/24/2003WO2003106411A1 24-sulfoximine vitamin d3 compounds
12/24/2003WO2003106410A1 Fluorinated cycloalkyl-derivatised benzoylguanidines and their use as a medicament
12/24/2003WO2003106401A1 N-bridged selective androgen receptor modulators and methods of use thereof
12/24/2003WO2003106394A1 Preparations containing conjugated linoleic alcohol
12/24/2003WO2003106381A2 Human adam-10 inhibitors
12/24/2003WO2003106380A2 Fluorobenzamides
12/24/2003WO2003105897A1 Combined use of a modulator of cd3 and a glp-1 compound
12/24/2003WO2003105896A1 Combined use of a modulator of cd3 and a beta cell resting compound
12/24/2003WO2003105893A2 Probiotic therapies
12/24/2003WO2003105882A1 Composition comprising viscous fibers and viscosity-lowering proteins
12/24/2003WO2003105873A1 Tailor-made preparation and process for producing the same
12/24/2003WO2003105850A1 2-aminoquinolines as melanin concentrating hormone receptor antagonists
12/24/2003WO2003105848A1 Controlled-release drug composition
12/24/2003WO2003105847A1 Ophthalmic compositions for treating ocular hypertension
12/24/2003WO2003105838A2 Metabolite
12/24/2003WO2003105837A1 Calcium salts of indole derived statins
12/24/2003WO2003105834A1 Bazedoxifene treatment regimens
12/24/2003WO2003105815A1 Combination of pde-v inhibitors and nk1 antagonists for the treatment of depression
12/24/2003WO2003105771A2 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
12/24/2003WO2003091232A3 Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them
12/24/2003WO2003088765A3 Functional foods containing a phospholipid-containing stable matrix
12/24/2003WO2003086102A3 Method for the production of potato juice products by means of food technology
12/24/2003WO2003084940B1 Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
12/24/2003WO2003084916A3 Compounds that modulate ppar activity and methods for their preparation
12/24/2003WO2003082807A3 Amino acids with affinity for the alpha-2-delta-protein
12/24/2003WO2003076414A3 Aryl substituted pyrimidines and the use thereof
12/24/2003WO2003072558A3 Arylsulfone derivatives
12/24/2003WO2003070914A3 RNA INTERFERENCE MEDIATED INHIBITION OF FOS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
12/24/2003WO2003068760A3 Compounds possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders
12/24/2003WO2003068231A3 Preparations containing folic acid, vitamin b6, and vitamin b12, and use thereof
12/24/2003WO2003068166A3 Treatment of ophthalmic disorders using urea and urea derivatives
12/24/2003WO2003066806A3 Therapeutic use of aziridino compounds
12/24/2003WO2003063800A3 8-heteroaryl xanthine adenosine a2b receptor antagonists
12/24/2003WO2003062236A8 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES
1 ... 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 ... 1298